Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)

This publication has 10 references indexed in Scilit:

• Management of Newly Diagnosed HIV Infection
  New England Journal of Medicine, 2005
• Monoclonal antibodies and fusion proteins in medicine
  Journal of Allergy and Clinical Immunology, 2005
• Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors
  Journal of Virology, 2005
• Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV‐1 Infection
  The Journal of Infectious Diseases, 2005
• The Appealing Story of HIV Entry Inhibitors
  Drugs, 2005
• Evolution of Human Immunodeficiency Virus Type 1 Coreceptor Usage during Antiretroviral Therapy: a Bayesian Approach
  Journal of Virology, 2004
• Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542
  Antimicrobial Agents and Chemotherapy, 2004
• The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C
  Journal of Virology, 2003
• Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140
  Journal of Virology, 2001
• Recombinant CD4‐IgG2 in Human Immunodeficiency Virus Type 1–Infected Children: Phase 1/2 Study
  The Journal of Infectious Diseases, 2000